Clinical Characteristics of Patients and Factors Associated with Switching Biologics in Asthma

Matsumoto-Sasaki, Machiko; Simizu, Kaoruko; Suzuki, Masanobu; Suzuki, Masaru; Kimura, Hirokazu; Nakamaru, Yuji; Ito, Yoichi M.; Honma, Akihiro; Konno, Satoshi

Clinical Characteristics of Patients and Factors Associated with Switching Biologics in Asthma

Matsumoto-Sasaki, Machiko; Simizu, Kaoruko; Suzuki, Masanobu et al.

Journal of Asthma and Allergy, 2022, 15, 187-195

Permalink : https://hdl.handle.net/2115/84684

このアイテムのアクセス数:486件（2026-03-12 18:02 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.2147/JAA.S348513			4

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	metadata only access
URI	https://hdl.handle.net/2115/84684
タイトル	Clinical Characteristics of Patients and Factors Associated with Switching Biologics in Asthma
著者	Matsumoto-Sasaki, Machiko ; Simizu, Kaoruko ; Suzuki, Masanobu ; Suzuki, Masaru ; Kimura, Hirokazu ; Nakamaru, Yuji ; Ito, Yoichi M. ; Honma, Akihiro ; Konno, Satoshi
著者名 Matsumoto-Sasaki, Machiko
著者名 Simizu, Kaoruko
e-Rad_Researcher 70455658 著者名 Suzuki, Masanobu
e-Rad_Researcher 10374290 著者名 Suzuki, Masaru
e-Rad_Researcher 90789330 著者名 Kimura, Hirokazu
e-Rad_Researcher 20344509 著者名 Nakamaru, Yuji
e-Rad_Researcher 10334236 著者名 Ito, Yoichi M.
著者名 Honma, Akihiro
e-Rad_Researcher 20399835 著者名 Konno, Satoshi
言語	英語
キーワード	aspirin-exacerbated respiratory disease
	asthma
	biologics
	comorbidities
	eosinophilic chronic rhinosinusitis
発行日	2022-02-09
出版者	Dove Medical Press
収録物名	Journal of Asthma and Allergy
巻(号)	15
ページ	187-195
抄録	Purpose: Biologics have been used increasingly for the treatment of severe asthma. However, established guidelines for the selection, switching, or discontinuation of biologics do not exist. We aimed to identify the clinical characteristics of patients with asthma who required switching biologics and the factors associated with switching biologics. Patients and Methods: This was a retrospective study of 42 patients with severe asthma treated with biologics at the Hokkaido University Hospital between 23rd June 2016 and 30th April 2021, when two biologics were available in Japan. We compared the characteristics of subjects who continued and switched biologics. The time to switch the biologics was assessed by type 2 inflammatory biomarkers, pulmonary function indices, and the presence of comorbidities, including the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis (JESREC) score and aspirin exacerbated respiratory diseases (AERD), using the Kaplan-Meier method and a multivariate Cox proportional hazards model. Results: Eight and five patients were treated by mepolizumab and benralizumab at baseline, respectively among the 31% (13/42) who switched the biologics. Subjects who required switching biologics were characterized by high blood eosinophil counts, younger age, JESREC scores of 11 points or higher, and AERD. The time taken to switch biologics was significantly shorter in the subgroups with high JESREC scores (>11) or AERD, compared with their counterparts with low JESREC scores or without AERD (both, P < 0.05). JESREC scores of >11, but not the presence of AERD, were associated with time to switch biologics. Conclusion: The presence of eosinophilic chronic rhinosinusitis based on JESREC scores of >11 and younger age were factors associated with switching biologics in asthma.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	1178-6965
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.2147/JAA.S348513